AVANOS MEDICAL, INC.AVNSEarnings & Financial Report
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Revenue
$170.4M
Gross Profit
$92.9M
Operating Profit
$12.0M
Net Profit
$4.3M
Gross Margin
54.5%
Operating Margin
7.0%
Net Margin
2.5%
YoY Growth
-0.5%
EPS
$0.09
AVANOS MEDICAL, INC. Q3 FY2024 Financial Summary
AVANOS MEDICAL, INC. reported revenue of $170.4M (down 0.5% YoY) for Q3 FY2024, with a net profit of $4.3M (up 216.2% YoY) (2.5% margin). Cost of goods sold was $77.5M, operating expenses totaled $80.9M.
Key Financial Metrics
| Total Revenue | $170.4M |
|---|---|
| Net Profit | $4.3M |
| Gross Margin | 54.5% |
| Operating Margin | 7.0% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
AVANOS MEDICAL, INC. Q3 FY2024 revenue of $170.4M breaks down across 4 segments, led by Digestive Health at $98.2M (57.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Digestive Health | $98.2M | 57.6% |
| Interventional Pain | $41.9M | 24.6% |
| Surgical Pain And Recovery | $30.3M | 17.8% |
| Diros Technology Inc | $4.6M | 2.7% |
AVANOS MEDICAL, INC. Revenue by Segment — Quarterly Trend
AVANOS MEDICAL, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Digestive Health and Interventional Pain) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Surgical Pain And Recovery | $24.7M | $24.4M | $25.2M | $24.5M |
AVANOS MEDICAL, INC. Annual Revenue by Year
AVANOS MEDICAL, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $701.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $701.2M |
| 2024 | $687.8M |
| 2023 | $673.3M |
| 2022 | $684.1M |
AVANOS MEDICAL, INC. Quarterly Revenue & Net Profit History
AVANOS MEDICAL, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $180.9M | +0.7% | $-1.3M | -0.7% |
| Q3 FY2025 | $177.8M | +4.3% | $-1.4M | -0.8% |
| Q2 FY2025 | $175.0M | +1.9% | $-76.8M | -43.9% |
| Q1 FY2025 | $167.5M | +0.8% | $6.6M | 3.9% |
| Q4 FY2024 | $179.6M | +3.6% | $-397.3M | -221.2% |
| Q3 FY2024 | $170.4M | -0.5% | $4.3M | 2.5% |
| Q2 FY2024 | $171.7M | +1.4% | $1.8M | 1.0% |
| Q1 FY2024 | $166.1M | +4.3% | $-900.0K | -0.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $166.1M | $171.7M | $170.4M | $179.6M | $167.5M | $175.0M | $177.8M | $180.9M |
| YoY Growth | 4.3% | 1.4% | -0.5% | 3.6% | 0.8% | 1.9% | 4.3% | 0.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.66B | $1.66B | $1.66B | $1.15B | $1.11B | $1.04B | $1.07B | $1.07B |
| Liabilities | $433.4M | $435.8M | $426.5M | $325.7M | $268.4M | $262.7M | $289.7M | $295.5M |
| Equity | $1.23B | $1.22B | $1.23B | $828.5M | $839.4M | $776.3M | $778.0M | $778.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.0M | $27.8M | $23.0M | $57.9M | $25.7M | $6.8M | $14.0M | $28.2M |